Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Litifilimab (BIIB059) in SLE and CLE
NCT02847598Phase 2Completed
- Sponsor
- Biogen
- Start
- Oct 2016
- Primary completion
- Aug 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of litifilimab in systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), sponsored by Biogen. Started Oct 2016; status: completed.
02
Drugs
litifilimab
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT02847598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02847598.